首页> 外国专利> DEVELOPMENT AND EVALUATION OF NOVEL CHINESE MATERIA MEDICA PREPARATIONS

DEVELOPMENT AND EVALUATION OF NOVEL CHINESE MATERIA MEDICA PREPARATIONS

机译:新型中药制剂的开发与评价。

摘要

Nuclear receptor LXR is an important member of 49 nuclear receptors in human bodies and has irreplaceable regulatory effects on cholesterol and fat metabolisms. The regulation of the biological activity of LXR may have therapeutic effects to the conditions such as cardiovascular and cerebrovascular obstructions, non-insulin dependent hyperglycemia, immune function disorders, and central nerve functional degeneration. We have developed a group of novel Chinese materia medica preparations targeting nuclear receptor LXR by using a computer-simulated docking technology and a process for determining biological activities of human cells cultured ex vivo. The group of preparations are featured by simple ingredients, low costs, easy to prepare, etc. No significant adverse effects were found in initial acute toxicology analysis which was carried out using mice.
机译:核受体LXR是人体49种核受体的重要成员,对胆固醇和脂肪代谢具有不可替代的调节作用。 LXR生物学活性的调节可能对诸如心血管和脑血管阻塞,非胰岛素依赖性高血糖,免疫功能紊乱和中枢神经功能变性等疾病具有治疗作用。通过使用计算机模拟的对接技术和确定离体培养的人类细胞生物活性的方法,我们已经开发出了一组针对核受体LXR的新型中药制剂。该组制剂的特点是成分简单,成本低廉,易于制备等。在使用小鼠进行的初始急性毒理学分析中未发现明显的不良反应。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号